Ixabepilone for the treatment of taxane-refractory breast cancer

Related Experiment Video

Updated: Jul 4, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Stacy L Moulder1

  • 1University of Texas, Breast Medical Oncology, Unit 1354, MD Anderson Cancer Center, PO Box 301438, 1155 Pressler Street, Houston, TX 77030, USA. smoulder@mdanderson.org

Future Oncology (London, England)
|June 4, 2008
PubMed

Insights

Ixabepilone is a novel microtubule-stabilizing agent approved for taxane-refractory metastatic breast cancer. This review details its clinical development and utility in advanced breast cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Ephothilones are a novel class of microtubule-targeting agents.
  • Ixabepilone, an epothilone B analog, exhibits potent preclinical anticancer activity.
  • Ixabepilone is approved in the US for specific breast cancer indications.

Purpose of the Study:

  • To review the clinical development of ixabepilone.
  • To highlight ixabepilone's efficacy in advanced breast cancer.
  • To discuss its role in taxane-refractory and multi-refractory breast cancer.

Main Methods:

  • Review of preclinical studies and clinical trials.
  • Analysis of data from pivotal Phase II and III studies.
  • Evaluation of ixabepilone as a single agent and in combination therapy.

Main Results:

  • Ixabepilone demonstrated significant activity in taxane-refractory metastatic breast cancer.
  • Combination therapy with capecitabine showed efficacy in anthracycline- and taxane-refractory patients.
  • Favorable safety profile observed, with manageable toxicities.

Conclusions:

  • Ixabepilone represents a valuable therapeutic option for advanced breast cancer.
  • It offers a new treatment avenue for patients with limited options.
  • Further research may explore its role in other cancer types.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...